HCPCS · Treatment J1010 Injection, methylprednisolone acetate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 151.74M services · est. · 881,642 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 74.84M observed fee-for-service services

See the national market for J1010 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2403 Chloroprocaine hcl ophthalmic, 3% gel, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 137.29M services · est. ▲ 585.4% YoY · 37,968 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 73.29M observed fee-for-service services

See the national market for J2403 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1439 Injection, ferric carboxymaltose, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 76.03M services · est. ▼ 14.4% YoY · 30,893 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 38.34M observed fee-for-service services

See the national market for J1439 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0878 Injection, daptomycin, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 59.77M services · est. ▼ 16.7% YoY · 5,508 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 27.81M observed fee-for-service services

See the national market for J0878 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1071 Injection, testosterone cypionate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 48.93M services · est. ▼ 4.9% YoY · 15,658 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 23.69M observed fee-for-service services

See the national market for J1071 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 34.31M services · est. ▲ 7.6% YoY · 2.36M FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 17.04M observed fee-for-service services

See the national market for J3301 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1100 Injection, dexamethasone sodium phosphate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 31.41M services · est. ▲ 1.6% YoY · 1.08M FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 15.45M observed fee-for-service services

See the national market for J1100 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1306 Injection, inclisiran, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 25.21M services · est. ▲ 110.6% YoY · 29,761 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 12.44M observed fee-for-service services

See the national market for J1306 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1453 Injection, fosaprepitant, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 23.81M services · est. ▲ 1.9% YoY · 30,895 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 11.84M observed fee-for-service services

See the national market for J1453 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0185 Injection, aprepitant, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 15.45M services · est. ▼ 3.0% YoY · 21,217 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7.83M observed fee-for-service services

See the national market for J0185 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3145 Injection, testosterone undecanoate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 10.71M services · est. ▲ 9.7% YoY · 2,440 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5.32M observed fee-for-service services

See the national market for J3145 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1437 Injection, ferric derisomaltose, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 7.48M services · est. ▲ 81.2% YoY · 31,211 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.75M observed fee-for-service services

See the national market for J1437 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2356 Injection, tezepelumab-ekko, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 7.26M services · est. ▲ 131.6% YoY · 3,550 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.54M observed fee-for-service services

See the national market for J2356 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 7.04M services · est. ▲ 212.4% YoY · 2,470 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.67M observed fee-for-service services

See the national market for Q5125 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3304 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 5.48M services · est. ▲ 3.9% YoY · 40,675 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.76M observed fee-for-service services

See the national market for J3304 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0872 Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 5.29M services · est. · 326 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.64M observed fee-for-service services

See the national market for J0872 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0588 Injection, incobotulinumtoxin a, 1 unit CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 5.18M services · est. ▲ 16.8% YoY · 5,791 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.51M observed fee-for-service services

See the national market for J0588 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2469 Injection, palonosetron hcl, 25 mcg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 5.15M services · est. ▲ 0.2% YoY · 83,932 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.56M observed fee-for-service services

See the national market for J2469 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2919 Injection, methylprednisolone sodium succinate, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 4.88M services · est. · 57,997 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.39M observed fee-for-service services

See the national market for J2919 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2781 Injection, pegcetacoplan, intravitreal, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 4.87M services · est. ▲ 511.6% YoY · 28,892 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.45M observed fee-for-service services

See the national market for J2781 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 4.55M services · est. ▲ 645.5% YoY · 41,929 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.26M observed fee-for-service services

See the national market for J0665 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4.23M services · est. ▼ 1.0% YoY · 612,919 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.08M observed fee-for-service services

See the national market for J0702 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0696 Injection, ceftriaxone sodium, per 250 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3.54M services · est. ▼ 0.3% YoY · 292,152 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.69M observed fee-for-service services

See the national market for J0696 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2405 Injection, ondansetron hydrochloride, per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 2.85M services · est. ▼ 10.3% YoY · 43,729 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.43M observed fee-for-service services

See the national market for J2405 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1627 Injection, granisetron, extended-release, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 2.02M services · est. ▲ 22.5% YoY · 4,508 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.11M observed fee-for-service services

See the national market for J1627 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1626 Injection, granisetron hydrochloride, 100 mcg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.95M services · est. ▼ 2.9% YoY · 28,893 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 972,377 observed fee-for-service services

See the national market for J1626 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1885 Injection, ketorolac tromethamine, per 15 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.94M services · est. ▼ 12.6% YoY · 213,169 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 930,781 observed fee-for-service services

See the national market for J1885 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.89M services · est. ▼ 4.8% YoY · 263,372 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 921,902 observed fee-for-service services

See the national market for J3420 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0586 Injection, abobotulinumtoxina, 5 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.74M services · est. ▲ 13.4% YoY · 1,848 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 812,876 observed fee-for-service services

See the national market for J0586 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0875 Injection, dalbavancin, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 1.71M services · est. ▼ 12.1% YoY · 2,239 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 833,120 observed fee-for-service services

See the national market for J0875 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3300 Injection, triamcinolone acetonide, preservative free, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.50M services · est. ▼ 33.3% YoY · 11,055 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 765,969 observed fee-for-service services

See the national market for J3300 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2704 Injection, propofol, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 1.48M services · est. ▼ 19.3% YoY · 30,439 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 736,132 observed fee-for-service services

See the national market for J2704 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1434 Injection, fosaprepitant (focinvez), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 1.45M services · est. · 1,802 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 723,351 observed fee-for-service services

See the national market for J1434 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1097 Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 1.36M services · est. ▼ 15.1% YoY · 106,949 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 697,684 observed fee-for-service services

See the national market for J1097 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2795 Injection, ropivacaine hydrochloride, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.32M services · est. ▼ 2.1% YoY · 9,467 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 644,374 observed fee-for-service services

See the national market for J2795 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q2028 Injection, sculptra, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 1.31M services · est. ▲ 47.5% YoY · 129 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 652,266 observed fee-for-service services

See the national market for Q2028 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0121 Injection, omadacycline, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 1.07M services · est. ▲ 83.8% YoY · 279 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 532,710 observed fee-for-service services

See the national market for J0121 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0153 Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 1.07M services · est. ▼ 48.1% YoY · 9,848 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 486,020 observed fee-for-service services

See the national market for J0153 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3489 Injection, zoledronic acid, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 1.02M services · est. ▲ 9.5% YoY · 86,520 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 509,798 observed fee-for-service services

See the national market for J3489 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7050 Infusion, normal saline solution, 250 cc CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 913,033 services · est. ▼ 3.5% YoY · 99,887 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 446,210 observed fee-for-service services

See the national market for J7050 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1171 Injection, hydromorphone, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 848,944 services · est. · 229 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 423,427 observed fee-for-service services

See the national market for J1171 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0873 Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 825,432 services · est. · 209 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 411,700 observed fee-for-service services

See the national market for J0873 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0461 Injection, atropine sulfate, 0.01 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 820,648 services · est. ▼ 6.1% YoY · 4,132 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 419,880 observed fee-for-service services

See the national market for J0461 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1200 Injection, diphenhydramine hcl, up to 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 811,031 services · est. ▼ 1.4% YoY · 124,105 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 402,518 observed fee-for-service services

See the national market for J1200 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1952 Leuprolide injectable, camcevi, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 719,089 services · est. ▲ 85.1% YoY · 6,743 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 368,147 observed fee-for-service services

See the national market for J1952 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1096 Dexamethasone, lacrimal ophthalmic insert, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 689,080 services · est. ▲ 14.8% YoY · 54,601 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 356,215 observed fee-for-service services

See the national market for J1096 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1030 Injection, methylprednisolone acetate, 40 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 611,809 services · est. ▼ 77.5% YoY · 182,811 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 302,105 observed fee-for-service services

See the national market for J1030 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0491 Injection, anifrolumab-fnia, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 571,533 services · est. ▲ 84.9% YoY · 192 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 280,825 observed fee-for-service services

See the national market for J0491 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0642 Injection, levoleucovorin (khapzory), 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 536,762 services · est. ▼ 39.2% YoY · 51 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 267,720 observed fee-for-service services

See the national market for J0642 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3475 Injection, magnesium sulfate, per 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 499,943 services · est. ▲ 0.9% YoY · 18,488 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 249,651 observed fee-for-service services

See the national market for J3475 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2250 Injection, midazolam hydrochloride, per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 496,420 services · est. ▼ 12.2% YoY · 59,666 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 243,537 observed fee-for-service services

See the national market for J2250 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0641 Injection, levoleucovorin, not otherwise specified, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 486,672 services · est. · 76 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 242,737 observed fee-for-service services

See the national market for J0641 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7030 Infusion, normal saline solution , 1000 cc CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 459,758 services · est. ▲ 2.6% YoY · 88,006 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 228,996 observed fee-for-service services

See the national market for J7030 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0248 Injection, remdesivir, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 446,760 services · est. · 1,298 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 222,830 observed fee-for-service services

See the national market for J0248 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0612 Injection, calcium gluconate, not otherwise specified, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 386,658 services · est. ▲ 161.9% YoY · 921 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 192,853 observed fee-for-service services

See the national market for J0612 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3121 Injection, testosterone enanthate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 377,072 services · est. ▼ 29.0% YoY · 229 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 188,072 observed fee-for-service services

See the national market for J3121 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1040 Injection, methylprednisolone acetate, 80 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 319,247 services · est. ▼ 78.8% YoY · 117,898 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 155,744 observed fee-for-service services

See the national market for J1040 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 316,137 services · est. ▼ 1.4% YoY · 49,874 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 158,461 observed fee-for-service services

See the national market for J7040 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 313,777 services · est. ▼ 23.4% YoY · 19,339 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 157,983 observed fee-for-service services

See the national market for J2001 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2185 Injection, meropenem, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 309,089 services · est. ▼ 6.5% YoY · 661 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 154,164 observed fee-for-service services

See the national market for J2185 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3480 Injection, potassium chloride, per 2 meq CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 274,127 services · est. ▼ 9.7% YoY · 5,814 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 140,454 observed fee-for-service services

See the national market for J3480 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3010 Injection, fentanyl citrate, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 268,297 services · est. ▼ 31.5% YoY · 35,006 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 131,545 observed fee-for-service services

See the national market for J3010 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0587 Injection, rimabotulinumtoxinb, 100 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 241,760 services · est. ▼ 13.8% YoY · 865 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 119,118 observed fee-for-service services

See the national market for J0587 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1955 Injection, levocarnitine, per 1 gm CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 230,197 services · est. ▼ 33.6% YoY · 2,172 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 116,670 observed fee-for-service services

See the national market for J1955 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2274 Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 207,157 services · est. ▼ 22.4% YoY · 651 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 94,517 observed fee-for-service services

See the national market for J2274 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1335 Injection, ertapenem sodium, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 195,028 services · est. ▼ 4.3% YoY · 8,841 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 92,228 observed fee-for-service services

See the national market for J1335 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3415 Injection, pyridoxine hcl, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 188,866 services · est. ▼ 31.8% YoY · 6,221 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 101,048 observed fee-for-service services

See the national market for J3415 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2406 Injection, oritavancin (kimyrsa), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 187,985 services · est. ▲ 7.4% YoY · 480 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 93,761 observed fee-for-service services

See the national market for J2406 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2248 Injection, micafungin sodium, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 179,243 services · est. ▲ 70.1% YoY · 67 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 89,401 observed fee-for-service services

See the national market for J2248 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1170 Injection, hydromorphone, up to 4 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 174,230 services · est. · 1,094 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 82,391 observed fee-for-service services

See the national market for J1170 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0692 Injection, cefepime hydrochloride, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 157,975 services · est. ▲ 10.1% YoY · 1,709 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 78,793 observed fee-for-service services

See the national market for J0692 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3411 Injection, thiamine hcl, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 147,446 services · est. ▼ 34.6% YoY · 4,215 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 80,512 observed fee-for-service services

See the national market for J3411 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 132,461 services · est. ▲ 0.5% YoY · 1,330 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 68,877 observed fee-for-service services

See the national market for J2916 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0131 Injection, acetaminophen, not otherwise specified,10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 125,611 services · est. · 457 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 62,786 observed fee-for-service services

See the national market for J0131 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7351 Injection, bimatoprost, intracameral implant, 1 microgram CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 114,265 services · est. ▼ 7.7% YoY · 3,423 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 56,428 observed fee-for-service services

See the national market for J7351 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3095 Injection, telavancin, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 112,928 services · est. ▼ 50.1% YoY · 66 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 56,325 observed fee-for-service services

See the national market for J3095 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1580 Injection, garamycin, gentamicin, up to 80 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 112,606 services · est. ▲ 5.4% YoY · 29,570 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 55,422 observed fee-for-service services

See the national market for J1580 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1456 Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 107,832 services · est. ▲ 110.9% YoY · 140 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 53,700 observed fee-for-service services

See the national market for J1456 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0589 Injection, daxibotulinumtoxina-lanm, 1 unit CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 99,556 services · est. · 99 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 48,420 observed fee-for-service services

See the national market for J0589 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2426 Injection, paliperidone palmitate extended release (invega sustenna), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 94,400 services · est. ▼ 22.1% YoY · 124 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 47,084 observed fee-for-service services

See the national market for J2426 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1050 Injection, medroxyprogesterone acetate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 77,822 services · est. ▼ 9.0% YoY · 160 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 38,815 observed fee-for-service services

See the national market for J1050 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0690 Injection, cefazolin sodium, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 77,481 services · est. ▼ 0.1% YoY · 10,873 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 39,553 observed fee-for-service services

See the national market for J0690 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0475 Injection, baclofen, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 77,457 services · est. ▼ 8.6% YoY · 2,591 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 38,526 observed fee-for-service services

See the national market for J0475 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1201 Injection, cetirizine hydrochloride, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 77,171 services · est. ▲ 143.9% YoY · 651 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 34,815 observed fee-for-service services

See the national market for J1201 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0280 Injection, aminophyllin, up to 250 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 72,869 services · est. ▼ 4.4% YoY · 32,204 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 36,689 observed fee-for-service services

See the national market for J0280 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3243 Injection, tigecycline, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 68,048 services · est. ▲ 38.4% YoY · 15 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 33,940 observed fee-for-service services

See the national market for J3243 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2002 Injection, lidocaine hcl in 5% dextrose, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 61,449 services · est. · 265 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 30,649 observed fee-for-service services

See the national market for J2002 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1020 Injection, methylprednisolone acetate, 20 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 57,188 services · est. ▼ 79.3% YoY · 12,919 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 29,784 observed fee-for-service services

See the national market for J1020 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3299 Injection, triamcinolone acetonide (xipere), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 54,940 services · est. ▲ 116.4% YoY · 539 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 27,502 observed fee-for-service services

See the national market for J3299 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2003 Injection, lidocaine hydrochloride, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 54,687 services · est. · 797 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 27,276 observed fee-for-service services

See the national market for J2003 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 52,151 services · est. ▼ 5.9% YoY · 9,773 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 25,883 observed fee-for-service services

See the national market for J1454 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1245 Injection, dipyridamole, per 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 52,104 services · est. ▼ 70.7% YoY · 4,846 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 24,663 observed fee-for-service services

See the national market for J1245 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3370 Injection, vancomycin hcl, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 51,260 services · est. ▼ 11.2% YoY · 841 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 24,212 observed fee-for-service services

See the national market for J3370 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2930 Injection, methylprednisolone sodium succinate, up to 125 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 46,608 services · est. ▼ 85.5% YoY · 11,578 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 22,871 observed fee-for-service services

See the national market for J2930 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3260 Injection, tobramycin sulfate, up to 80 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 45,305 services · est. · 6,093 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 22,597 observed fee-for-service services

See the national market for J3260 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0122 Injection, eravacycline, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 42,969 services · est. · 11 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 24,450 observed fee-for-service services

See the national market for J0122 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7060 5% dextrose/water (500 ml = 1 unit) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 39,806 services · est. ▲ 7.0% YoY · 2,712 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 19,842 observed fee-for-service services

See the national market for J7060 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2010 Injection, lincomycin hcl, up to 300 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 38,908 services · est. ▼ 5.0% YoY · 9,237 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 18,959 observed fee-for-service services

See the national market for J2010 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3396 Injection, verteporfin, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 29,590 services · est. ▼ 36.6% YoY · 96 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 15,536 observed fee-for-service services

See the national market for J3396 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1932 Injection, lanreotide, (cipla), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 28,592 services · est. · 25 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 13,320 observed fee-for-service services

See the national market for J1932 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2920 Injection, methylprednisolone sodium succinate, up to 40 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 25,869 services · est. ▼ 82.2% YoY · 6,014 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 12,320 observed fee-for-service services

See the national market for J2920 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1720 Injection, hydrocortisone sodium succinate, up to 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 24,114 services · est. ▲ 14.5% YoY · 4,290 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 11,728 observed fee-for-service services

See the national market for J1720 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0713 Injection, ceftazidime, per 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 21,357 services · est. ▲ 19.6% YoY · 186 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 10,652 observed fee-for-service services

See the national market for J0713 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2315 Injection, naltrexone, depot form, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 20,571 services · est. ▼ 76.1% YoY · 20 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 10,260 observed fee-for-service services

See the national market for J2315 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2543 Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 20,563 services · est. ▼ 23.6% YoY · 169 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,655 observed fee-for-service services

See the national market for J2543 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0291 Injection, plazomicin, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 20,282 services · est. ▼ 50.8% YoY · 23 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 11,541 observed fee-for-service services

See the national market for J0291 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7120 Ringers lactate infusion, up to 1000 cc CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 20,198 services · est. · 4,710 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 10,074 observed fee-for-service services

See the national market for J7120 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3315 Injection, triptorelin pamoate, 3.75 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 19,364 services · est. ▼ 12.5% YoY · 1,363 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,140 observed fee-for-service services

See the national market for J3315 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0222 Injection, bebtelovimab, 175 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 18,997 services · est. · 10,316 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 10,379 observed fee-for-service services

See the national market for Q0222 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q9950 Injection, sulfur hexafluoride lipid microspheres, per ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 18,274 services · est. ▼ 3.4% YoY · 2,219 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,249 observed fee-for-service services

See the national market for Q9950 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0278 Injection, amikacin sulfate, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 17,647 services · est. ▲ 11.5% YoY · 1,307 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 8,560 observed fee-for-service services

See the national market for J0278 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 16,836 services · est. · 552 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,152 observed fee-for-service services

See the national market for J2468 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2407 Injection, oritavancin (orbactiv), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 15,320 services · est. · 43 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7,320 observed fee-for-service services

See the national market for J2407 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0223 Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 13,961 services · est. · 7,642 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 7,686 observed fee-for-service services

See the national market for M0223 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1611 Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 11,512 services · est. ▲ 296.9% YoY · 5,286 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,742 observed fee-for-service services

See the national market for J1611 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2280 Injection, moxifloxacin, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 10,988 services · est. ▲ 102.9% YoY · 3,315 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,463 observed fee-for-service services

See the national market for J2280 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0610 Injection, calcium gluconate (fresenius kabi), per 10 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 10,325 services · est. ▼ 74.2% YoY · 1,041 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 5,335 observed fee-for-service services

See the national market for J0610 → ranked groups · states · 12-yr trend

HCPCS · Treatment P9047 Infusion, albumin (human), 25%, 50 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 9,590 services · est. ▼ 19.9% YoY · 277 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,783 observed fee-for-service services

See the national market for P9047 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1610 Injection, glucagon hydrochloride, per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 9,443 services · est. ▼ 18.7% YoY · 3,767 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,710 observed fee-for-service services

See the national market for J1610 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7042 5% dextrose/normal saline (500 ml = 1 unit) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 9,252 services · est. · 1,170 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,355 observed fee-for-service services

See the national market for J7042 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0561 Injection, penicillin g benzathine, 100,000 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 8,676 services · est. ▼ 26.1% YoY · 138 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,262 observed fee-for-service services

See the national market for J0561 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0670 Injection, mepivacaine hydrochloride, per 10 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 8,439 services · est. ▼ 28.4% YoY · 779 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,209 observed fee-for-service services

See the national market for J0670 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1836 Injection, metronidazole, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 8,170 services · est. · 101 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 4,451 observed fee-for-service services

See the national market for J1836 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0743 Injection, cilastatin sodium; imipenem, per 250 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 7,490 services · est. ▲ 380.2% YoY · 118 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,736 observed fee-for-service services

See the national market for J0743 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1956 Injection, levofloxacin, 250 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 6,656 services · est. ▼ 21.3% YoY · 460 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,320 observed fee-for-service services

See the national market for J1956 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0583 Injection, bivalirudin, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 6,516 services · est. ▼ 80.8% YoY · 12 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,250 observed fee-for-service services

See the national market for J0583 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1212 Injection, dmso, dimethyl sulfoxide, 50%, 50 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 6,472 services · est. ▲ 18.5% YoY · 223 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,228 observed fee-for-service services

See the national market for J1212 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2270 Injection, morphine sulfate, up to 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 6,380 services · est. ▲ 121.1% YoY · 316 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,182 observed fee-for-service services

See the national market for J2270 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7314 Injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 6,111 services · est. ▲ 142.5% YoY · 144 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,115 observed fee-for-service services

See the national market for J7314 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2360 Injection, orphenadrine citrate, up to 60 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 6,110 services · est. ▼ 24.6% YoY · 1,621 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,810 observed fee-for-service services

See the national market for J2360 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0735 Injection, clonidine hydrochloride, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 5,154 services · est. ▲ 14.6% YoY · 397 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,399 observed fee-for-service services

See the national market for J0735 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0225 Injection, vutrisiran, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 5,054 services · est. ▲ 37.3% YoY · 60 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,521 observed fee-for-service services

See the national market for J0225 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0945 Injection, brompheniramine maleate, per 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4,920 services · est. ▲ 6.8% YoY · 1,352 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,454 observed fee-for-service services

See the national market for J0945 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2400 Injection, chloroprocaine hydrochloride, per 30 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4,810 services · est. · 291 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 2,606 observed fee-for-service services

See the national market for J2400 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1250 Injection, dobutamine hydrochloride, per 250 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4,525 services · est. ▼ 25.1% YoY · 2,080 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,250 observed fee-for-service services

See the national market for J1250 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0613 Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 4,315 services · est. ▲ 7.5% YoY · 44 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,152 observed fee-for-service services

See the national market for J0613 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2175 Injection, meperidine hydrochloride, per 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4,204 services · est. ▼ 23.3% YoY · 1,522 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,260 observed fee-for-service services

See the national market for J2175 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1380 Injection, estradiol valerate, up to 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4,147 services · est. ▼ 3.7% YoY · 208 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,927 observed fee-for-service services

See the national market for J1380 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3360 Injection, diazepam, up to 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 4,078 services · est. ▲ 5.6% YoY · 811 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,052 observed fee-for-service services

See the national market for J3360 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1631 Injection, haloperidol decanoate, per 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,915 services · est. ▼ 24.8% YoY · 87 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,854 observed fee-for-service services

See the national market for J1631 → ranked groups · states · 12-yr trend

HCPCS · Treatment P9046 Infusion, albumin (human), 25%, 20 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 3,819 services · est. ▼ 18.2% YoY · 54 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,905 observed fee-for-service services

See the national market for P9046 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2371 Injection, phenylephrine hydrochloride, 20 micrograms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 3,785 services · est. ▲ 7724.0% YoY · 53 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,888 observed fee-for-service services

See the national market for J2371 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1954 Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 3,771 services · est. ▲ 218.4% YoY · 283 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,881 observed fee-for-service services

See the national market for J1954 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2550 Injection, promethazine hcl, up to 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,593 services · est. ▼ 32.8% YoY · 932 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,754 observed fee-for-service services

See the national market for J2550 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1939 Injection, bumetanide, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 3,549 services · est. · 263 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,042 observed fee-for-service services

See the national market for J1939 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7313 Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 3,526 services · est. ▼ 21.2% YoY · 78 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,787 observed fee-for-service services

See the national market for J7313 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2805 Injection, sincalide, 5 micrograms CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,471 services · est. ▼ 15.2% YoY · 1,744 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,759 observed fee-for-service services

See the national market for J2805 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3303 Injection, triamcinolone hexacetonide, per 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,355 services · est. ▲ 33.5% YoY · 355 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 1,849 observed fee-for-service services

See the national market for J3303 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0689 Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 3,240 services · est. ▲ 1893.1% YoY · 379 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,616 observed fee-for-service services

See the national market for J0689 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2060 Injection, lorazepam, 2 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,229 services · est. ▼ 40.5% YoY · 573 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,625 observed fee-for-service services

See the national market for J2060 → ranked groups · states · 12-yr trend

HCPCS · Treatment J9209 Injection, mesna, 200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,091 services · est. ▲ 31.4% YoY · 11 FFS beneficiary-episodes (CY2020, all-Medicare estimate) — 1,858 observed fee-for-service services

See the national market for J9209 → ranked groups · states · 12-yr trend

HCPCS · Treatment L8607 Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 3,057 services · est. ▼ 2.3% YoY · 183 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,553 observed fee-for-service services

See the national market for L8607 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1740 Injection, ibandronate sodium, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 2,946 services · est. ▼ 23.9% YoY · 215 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,459 observed fee-for-service services

See the national market for J1740 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0171 Injection, adrenalin, epinephrine, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 2,768 services · est. ▼ 2.7% YoY · 650 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,337 observed fee-for-service services

See the national market for J0171 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1000 Injection, depo-estradiol cypionate, up to 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 2,710 services · est. ▲ 53.8% YoY · 363 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,310 observed fee-for-service services

See the national market for J1000 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2562 Injection, plerixafor, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 2,221 services · est. ▼ 35.7% YoY · 32 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,108 observed fee-for-service services

See the national market for J2562 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0132 Injection, acetylcysteine, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 2,147 services · est. ▲ 151.0% YoY · 199 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,071 observed fee-for-service services

See the national market for J0132 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0290 Injection, ampicillin sodium, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 2,079 services · est. · 300 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,037 observed fee-for-service services

See the national market for J0290 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7070 Infusion, d5w, 1000 cc CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,957 services · est. · 392 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 976 observed fee-for-service services

See the national market for J7070 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2765 Injection, metoclopramide hcl, up to 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,859 services · est. · 339 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 936 observed fee-for-service services

See the national market for J2765 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2675 Injection, progesterone, per 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,835 services · est. ▲ 28.6% YoY · 118 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 915 observed fee-for-service services

See the national market for J2675 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2800 Injection, methocarbamol, up to 10 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,745 services · est. ▼ 31.1% YoY · 420 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 786 observed fee-for-service services

See the national market for J2800 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0600 Injection, edetate calcium disodium, up to 1000 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,588 services · est. ▼ 46.3% YoY · 71 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 792 observed fee-for-service services

See the national market for J0600 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0895 Injection, deferoxamine mesylate, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,517 services · est. ▲ 27.2% YoY · 11 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 784 observed fee-for-service services

See the national market for J0895 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0736 Injection, clindamycin phosphate, 300 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 1,514 services · est. · 375 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 752 observed fee-for-service services

See the national market for J0736 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2300 Injection, nalbuphine hydrochloride, per 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,462 services · est. · 157 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 729 observed fee-for-service services

See the national market for J2300 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0295 Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,438 services · est. ▼ 46.8% YoY · 121 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 717 observed fee-for-service services

See the national market for J0295 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0595 Injection, butorphanol tartrate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,226 services · est. · 77 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 664 observed fee-for-service services

See the national market for J0595 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0698 Injection, cefotaxime sodium, per gm CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,194 services · est. ▲ 6.9% YoY · 334 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 587 observed fee-for-service services

See the national market for J0698 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1950 Injection, leuprolide acetate (for depot suspension), per 3.75 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,155 services · est. ▲ 168.8% YoY · 48 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 576 observed fee-for-service services

See the national market for J1950 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3250 Injection, trimethobenzamide hcl, up to 200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,099 services · est. ▼ 56.4% YoY · 225 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 548 observed fee-for-service services

See the national market for J3250 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2150 Injection, mannitol, 25% in 50 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,057 services · est. · 317 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 527 observed fee-for-service services

See the national market for J2150 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0780 Injection, prochlorperazine, up to 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 982 services · est. ▼ 20.6% YoY · 250 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 490 observed fee-for-service services

See the national market for J0780 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0694 Injection, cefoxitin sodium, 1 gm CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 978 services · est. · 289 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 488 observed fee-for-service services

See the national market for J0694 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3425 Injection, hydroxocobalamin, intramuscular, 10 mcg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 876 services · est. · 112 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 437 observed fee-for-service services

See the national market for J3425 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1920 Injection, labetalol hydrochloride, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 852 services · est. · 155 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 438 observed fee-for-service services

See the national market for J1920 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2680 Injection, fluphenazine decanoate, up to 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 778 services · est. · 40 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 388 observed fee-for-service services

See the national market for J2680 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2305 Injection, nitroglycerin, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 774 services · est. · 273 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 365 observed fee-for-service services

See the national market for J2305 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0834 Injection, cosyntropin, 0.25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 707 services · est. ▼ 8.9% YoY · 339 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 363 observed fee-for-service services

See the national market for J0834 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1240 Injection, dimenhydrinate, up to 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 706 services · est. ▼ 22.7% YoY · 136 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 352 observed fee-for-service services

See the national market for J1240 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0744 Injection, ciprofloxacin for intravenous infusion, 200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 670 services · est. · 165 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 334 observed fee-for-service services

See the national market for J0744 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3430 Injection, phytonadione (vitamin k), per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 660 services · est. ▼ 11.3% YoY · 39 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 341 observed fee-for-service services

See the national market for J3430 → ranked groups · states · 12-yr trend

HCPCS · Treatment P9041 Infusion, albumin (human), 5%, 50 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 658 services · est. ▼ 72.9% YoY · 71 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 328 observed fee-for-service services

See the national market for P9041 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2780 Injection, ranitidine hydrochloride, 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 612 services · est. ▼ 13.7% YoY · 25 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 305 observed fee-for-service services

See the national market for J2780 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1205 Injection, chlorothiazide sodium, per 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 549 services · est. ▲ 61.3% YoY · 109 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 274 observed fee-for-service services

See the national market for J1205 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1953 Injection, levetiracetam, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 529 services · est. ▼ 0.2% YoY · 41 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 264 observed fee-for-service services

See the national market for J1953 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0500 Injection, dicyclomine hcl, up to 20 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 449 services · est. ▼ 54.1% YoY · 42 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 224 observed fee-for-service services

See the national market for J0500 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0287 Injection, amphotericin b lipid complex, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 409 services · est. ▼ 6.1% YoY · 54 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 204 observed fee-for-service services

See the national market for J0287 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3424 Injection, hydroxocobalamin, intravenous, 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 367 services · est. · 45 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 183 observed fee-for-service services

See the national market for J3424 → ranked groups · states · 12-yr trend

HCPCS · Treatment Q0224 Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medica CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 352 services · est. · 87 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 165 observed fee-for-service services

See the national market for Q0224 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2430 Injection, pamidronate disodium, per 30 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 341 services · est. · 23 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 176 observed fee-for-service services

See the national market for J2430 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1805 Injection, esmolol hydrochloride, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 333 services · est. · 48 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 166 observed fee-for-service services

See the national market for J1805 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0737 Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 330 services · est. · 61 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 155 observed fee-for-service services

See the national market for J0737 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0697 Injection, sterile cefuroxime sodium, per 750 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 275 services · est. ▼ 30.4% YoY · 94 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 137 observed fee-for-service services

See the national market for J0697 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1190 Injection, dexrazoxane hydrochloride, per 250 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 261 services · est. ▼ 46.1% YoY · 14 FFS beneficiary-episodes (CY2020, all-Medicare estimate) — 157 observed fee-for-service services

See the national market for J1190 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3410 Injection, hydroxyzine hcl, up to 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 255 services · est. ▼ 54.8% YoY · 108 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 127 observed fee-for-service services

See the national market for J3410 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0456 Injection, azithromycin, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 242 services · est. · 91 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 127 observed fee-for-service services

See the national market for J0456 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0224 Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 241 services · est. · 87 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 120 observed fee-for-service services

See the national market for M0224 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0401 Injection, aripiprazole (abilify maintena), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 192 services · est. ▼ 94.9% YoY · 25 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 96 observed fee-for-service services

See the national market for J0401 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3240 Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 191 services · est. · 52 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 86 observed fee-for-service services

See the national market for J3240 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0688 Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 160 services · est. · 36 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 80 observed fee-for-service services

See the national market for J0688 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1230 Injection, methadone hcl, up to 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 146 services · est. ▲ 9.6% YoY · 33 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 73 observed fee-for-service services

See the national market for J1230 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2440 Injection, papaverine hcl, up to 60 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 128 services · est. · 71 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 73 observed fee-for-service services

See the national market for J2440 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2370 Injection, phenylephrine hcl, up to 1 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 123 services · est. ▼ 64.3% YoY · 64 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 69 observed fee-for-service services

See the national market for J2370 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1110 Injection, dihydroergotamine mesylate, per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 114 services · est. ▲ 20.5% YoY · 25 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 57 observed fee-for-service services

See the national market for J1110 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 108 services · est. · 26 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 54 observed fee-for-service services

See the national market for J0687 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0133 Injection, acyclovir, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 106 services · est. · 14 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 53 observed fee-for-service services

See the national market for J0133 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7131 Hypertonic saline solution, 1 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 74 services · est. · 12 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 37 observed fee-for-service services

See the national market for J7131 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1364 Injection, erythromycin lactobionate, per 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 72 services · est. · 13 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 37 observed fee-for-service services

See the national market for J1364 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0480 Injection, basiliximab, 20 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 54 services · est. · 31 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 31 observed fee-for-service services

See the national market for J0480 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0592 Injection, buprenorphine hydrochloride, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 50 services · est. ▼ 85.7% YoY · 19 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 25 observed fee-for-service services

See the national market for J0592 → ranked groups · states · 12-yr trend

HCPCS · Treatment J0695 Injection, ceftolozane 50 mg and tazobactam 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 48 services · est. ▲ 55.4% YoY · 19 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 24 observed fee-for-service services

See the national market for J0695 → ranked groups · states · 12-yr trend

HCPCS · Treatment M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 46 services · est. · 24 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 24 observed fee-for-service services

See the national market for M0222 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1596 Injection, glycopyrrolate, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 44 services · est. · 11 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 22 observed fee-for-service services

See the national market for J1596 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3105 Injection, terbutaline sulfate, up to 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 44 services · est. · 11 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 22 observed fee-for-service services

See the national market for J3105 → ranked groups · states · 12-yr trend

HCPCS · Treatment J1450 Injection fluconazole, 200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 43 services · est. · 11 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 22 observed fee-for-service services

See the national market for J1450 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2310 Injection, naloxone hydrochloride, per 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 38 services · est. ▼ 67.7% YoY · 18 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 19 observed fee-for-service services

See the national market for J2310 → ranked groups · states · 12-yr trend

HCPCS · Treatment J2470 Injection, pantoprazole sodium, 40 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 30 services · est. · 13 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 15 observed fee-for-service services

See the national market for J2470 → ranked groups · states · 12-yr trend

Injections and Infusions (nononcologic) — codes without an RBCS family